“The 3billion service is exceptional[, the] portal is very friendly and easy to use[, and] raw data is made available in no time. Overall, [a] highly satisfactory experience.”

“Our collaboration with 3billion helped us in the genetic investigation of our patients with fast, reliable and easy to understand reports of WES datasets.”

Marcondes C. França, Jr., M.D., Ph.D.

Associate Professor, Neurology @ UNICAMP, Brazil

“The partnership with 3billion was extremely valuable in [advancing] research projects on rare congenital disease from my lab. The whole exome sequencing service provided was very fast, and a high molecular diagnosis was achieved (>50%).”

“I give to our collaborators at 3billion [a] special gratitude for their outstanding services that helped in ending the diagnostic odyssey for many of our patients with rare diseases.”

Ngu Lock Hock, M.D.

Consultant Clinical Geneticist & Head of Medical Genetics @ Hospital Kuala Lumpur, Malaysia

“[3billion] has been very valuable for the care of my patients and the conduction of my research. The results are very informative and illustrative.”

"3billion offers one of the most integrative services in genetic testing for rare diseases. Notably, the automated reanalysis tool for inconclusive cases is of extreme value for patient care.”

Juan Carlos Zenteno, M.D., Ph.D.

Head of Department of Genetics @ Institute of Ophthalmology "Conde de Valenciana," Mexico

“The 3billion service is exceptional[, the] portal is very friendly and easy to use[, and] raw data is made available in no time. Overall, [a] highly satisfactory experience.”

“Our collaboration with 3billion helped us in the genetic investigation of our patients with fast, reliable and easy to understand reports of WES datasets.”

Marcondes C. França, Jr., M.D., Ph.D.

Associate Professor, Neurology @ UNICAMP, Brazil

“The partnership with 3billion was extremely valuable in [advancing] research projects on rare congenital disease from my lab. The whole exome sequencing service provided was very fast, and a high molecular diagnosis was achieved (>50%).”